June 28, 2017 / 8:09 PM / a year ago

BRIEF-Gemphire announces top-line data from COBALT-1 phase 2b clinical trial in HoFH patients

* Gemphire announces top-line data from cobalt-1 phase 2b clinical trial in hofh patients

* Gemphire therapeutics inc - top-line data on ldl-c primary endpoint from completed open label phase 2b cobalt-1 trial

* Gemphire therapeutics - adverse events (aes) were mild to moderate in intensity across all doses of gemcabene and consistent with previously reported aes

* Gemphire therapeutics inc - there were no serious aes or withdrawals due to aes in cobalt-1 study

* Gemphire therapeutics - data announced continue to demonstrate additive lipid lowering efficacy of gemcabene has been demonstrated in extensive clinical program to date

* Gemphire therapeutics inc - hofh patients continue to have elevated ldl-c and additional therapies are needed to help these patients Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below